Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents
  • CME
  • MOC
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: October 28, 2022 Expiration: October 27, 2023
Start Activity
Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This CE activity is supported through an educational grant from
AstraZeneca
BeiGene
Lilly
Farrukh Awan, MD
Nicole Lamanna, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare first-generation and next-generation BTK inhibitors in terms of molecular characteristics, binding, targeted selectivity, approved indications, dosing, safety profile, and efficacy
  • Plan BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL, taking into consideration guidelines, expert recommendations, and recent practice-changing clinical trial results
  • Select optimal BTK inhibitor–based therapy in relapsed/refractory CLL/SLL for appropriate patients following progression on or intolerance of first-line or subsequent therapies
  • Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation and to maximize patient survival and quality of life
  • Identify patients eligible for ongoing clinical trials evaluating currently available and emerging BTK inhibitors and BTK inhibitor–based combinations

Information on this Educational Activity

Disclosure and Conflict of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Farrukh Awan, MD

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Division of Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS: consultant/advisor: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Cardinal Health, Caribou Biosciences, Celgene, Dava Oncology, Epizyme, Genentech, Gilead Sciences, Incyte, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, MEI Pharma, Merck, Pharmacyclics, Verastem.
Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Pharmacyclics.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz D. Constanzo, PhD, MBA, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose. 

All of the relevant financial relationships of individuals for this activity have been mitigated.

Target Audience

This educational program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with CLL/SLL.

Goal

The goal of this activity is to improve the knowledge, competence, and confidence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTKi in the care of their patients with CLL/SLL.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-0000-22-115-H01-P

Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learner information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2022, through October 27, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Evolving Role of BTK Inhibitors in CLL: Sequencing, Combinations, and Novel Agents
  • CME
  • MOC
  • CE

Loading...
Watch this on-demand webcast from a SOHO satellite symposium on BTK inhibitors for the management of CLL in frontline and the recurrent setting, including discussions on AE management and treatment sequencing.
Farrukh Awan, MD
Nicole Lamanna, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
Released: October 28, 2022 Expiration: October 27, 2023

Related Content

Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024
Provided by Medical Learning Institute, Inc. in partnership with Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This CE activity is supported through an educational grant from
AstraZeneca
BeiGene
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings